- Home
- BEAM vs NWBI Comparison
BEAM vs NWBI Comparison
Compare BEAM & NWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BEAM | NWBI |
|---|---|---|
| Founded | 2017 | 1896 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.8B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | BEAM | NWBI |
|---|---|---|
| Price | $28.05 | $12.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 2 |
| Target Price | ★ $48.09 | $14.00 |
| AVG Volume (30 Days) | ★ 1.6M | 912.0K |
| Earning Date | 11-04-2025 | 01-23-2026 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | N/A | ★ 0.86 |
| Revenue | $55,701,000.00 | ★ $564,562,000.00 |
| Revenue This Year | N/A | $7.91 |
| Revenue Next Year | $26.52 | $9.01 |
| P/E Ratio | ★ N/A | $14.23 |
| Revenue Growth | N/A | ★ 15.71 |
| 52 Week Low | $13.53 | $10.75 |
| 52 Week High | $35.25 | $13.62 |
Technical Indicators
Market Signals| Indicator | BEAM | NWBI |
|---|---|---|
| Relative Strength Index (RSI) | 60.74 | 48.07 |
| Support Level | $26.17 | $12.64 |
| Resistance Level | $28.64 | $12.90 |
| Average True Range (ATR) | 1.39 | 0.22 |
| MACD | 0.08 | -0.04 |
| Stochastic Oscillator | 78.14 | 19.48 |
Price Performance
Historical ComparisonAbout BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About NWBI Northwest Bancshares Inc.
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution offering personal and commercial banking business solutions, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and business banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Business banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.